Compare AbCellera Biologics Inc (ABCL) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

QCLN trades at $58.70, up 3.51% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces mixed sentiment amid clean energy sector volatility, with support at $55 and resistance at $60. Recent news highlights policy risks from stalled US permits and geopolitical tensions affecting solar supply chains, while global investment in renewables continues to grow.

Outlook remains cautious due to regulatory headwinds and cost pressures, though long-term clean energy demand provides upside potential. Key risks include US-China trade policies and inflation-driven installation costs, with investor sentiment divided between near-term challenges and structural growth opportunities.